Pioglitazone after ischemic stroke or Transient Ischemic attack

New England Journal of Medicine

Volumn 374, Issue 14, 2016, Pages 1321-1331

  Kernan, W N ^a   Viscoli, C M ^a   Furie, K L ^d   Young, L H ^a   Inzucchi, S E ^a   Gorman, M ^e   Guarino, P D ^b,c   Lovejoy, A M ^k   Peduzzi, P N ^b,c   Conwit, R ^f   Brass, L M ^a   Schwartz, G G ^g   Adams, H P ^h   Berger, L ⁱ   Carolei, A ^l   Clark, W ^m   Coull, B ⁿ   Ford, G A ^o   Kleindorfer, D ^p   O'Leary, J R ^a,b   Parsons, M W ^q   Ringleb, P ^r   Sen, S ^s   Spence, J D ^j   Tanne, D ^t   Wang, D ^u   Winder, T R ^a,b   more..

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF IOWA   (United States)

ⁱ HÔPITAL CHARLES LEMOYNE   (Canada)

^j UNIVERSITY OF WESTERN ONTARIO   (Canada)

^k Center for Neurological Research   (Canada)

^l UNIVERSITY OF L'AQUILA   (Italy)

^m OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁿ UNIVERSITY OF ARIZONA   (United States)

^o UNIVERSITY OF OXFORD   (United Kingdom)

^p UNIVERSITY OF CINCINNATI   (United States)

^q UNIVERSITY OF NEWCASTLE   (Australia)

^r UNIVERSITY OF HEIDELBERG   (Germany)

^s UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^t TEL AVIV UNIVERSITY   (Israel)

^u UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; PLACEBO; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ADULT; AGED; ARTICLE; BLADDER CANCER; BRAIN ISCHEMIA; BREAST CANCER; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DYSPNEA; EDEMA; FATALITY; FEMALE; FRACTURE; HEART FAILURE; HEART INFARCTION; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE INDEX; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIPOMA; LUNG CANCER; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK; WEIGHT GAIN; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; ISCHEMIC ATTACK, TRANSIENT; METABOLISM; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; STROKE;

AGED; BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; SECONDARY PREVENTION; STROKE; THIAZOLIDINEDIONES; WEIGHT GAIN;

EID: 84962114446     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1506930     Document Type: Article

References (52)

1. Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health 2013; 1(5): e25981.
2. Kleindorfer D, Panagos P, Pancioli A, et al. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 2005; 36: 720-3.
3. Dhamoon MS, Sciacca RR, Rundek T, Sacco RL, Elkind MS. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology 2006; 66: 641-6.
4. Johnston SC Transient ischemic attack. N Engl J Med 2002; 347: 1687-92.
5. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160-236.
6. Kernan WN, Inzucchi SE, Viscoli CM, et al. Impaired insulin sensitivity among nondiabetic patients with a recent TIA or ischemic stroke. Neurology 2003; 60: 144751.
7. Mather KJ, Steinberg HO, Baron AD. Insulin resistance in the vasculature. J Clin Invest 2013; 123: 1003-4.
8. Semenkovich CF Insulin resistance and atherosclerosis. J Clin Invest 2006; 116: 1813-22.
9. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI. Insulin resistance and risk for stroke. Neurology 2002; 59: 809-15.
10. Ivey FM, Ryan AS, Hafer-Macko CE, Goldberg AP, Macko RF. Treadmill aerobic training improves glucose tolerance and indices of insulin sensitivity in disabled stroke survivors: a preliminary report. Stroke 2007; 38: 2752-8.
11. Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 292: 1440-6.
12. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54: 603-8.
13. Kernan WN, Inzucchi SE, Viscoli CM, et al. Pioglitazone improves insulin sensitivity among non-diabetic patients with a recent TIA or ischemic stroke. Stroke 2003; 34: 1431-6.
14. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-72.
15. Wilcox R, Bousser M-G, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38: 865-73.
16. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macro-vascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
17. Viscoli CM, Brass LM, Carolei A, et al. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. Am Heart J 2014; 168(6): 823-9. e6.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
19. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. Diabet Med 1999; 16: 442-3.
20. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003; 26: 3320-5.
21. Huff TA, Lebovitz HE, Heyman A, Davis L. Serial changes in glucose utilization and insulin and growth hormone secretion in acute cerebrovascular disease. Stroke 1972; 3: 543-52.
22. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28: Suppl 1: S37-42.
23. Teng EL, Chui HC. The Modified Mini Mental State (3MS) examination. J Clin Psychiatry 1987; 48: 314-8.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
25. Cox DR Regression models and life-tables. J R Stat Soc [Ser A] 1972; 34: 187-202.
26. Efird JT, Nielsen SS. A method to compute multiplicity corrected confidence intervals for odds ratios and other relative effect estimates. Int J Environ Res Public Health 2008; 5: 394-8.
27. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800-2.
28. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 2064-89.
29. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020-35.
30. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010; 33: Suppl 1: S11-61.
31. The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503-15.
32. Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-73.
33. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572-81.
34. Saremi A, Schwenke DC, Buchanan TA, et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013; 33: 393-9.
35. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-18.
36. Basu R, Shah P, Basu A, et al. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes. Diabetes 2008; 57: 24-31.
37. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-91.
38. Aronoff S, Rosenblatt S, Braithwaite S, Egan J W, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000; 23: 1605-11.
39. Campia U, Matuskey LA, Panza JA. Peroxisome proliferator-activated receptorgamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006; 113: 867-75.
40. Di Gregorio GB, Yao-Borengasser A, Rasouli N, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005; 54: 2305-13.
41. Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11: 861-6.
42. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007; 370: 1129-36.
43. Zhu Z-N, Jiang Y-F, Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 2014; 68: 115-23.
44. Grey A, Bolland MJ, Fenwick S, et al. The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. Eur J Endocrinol 2014; 170: 255-62.
45. Bone HG, Lindsay R, McClung MR, Perez AT, Raanan MG, Spanheimer RG. Effects of pioglitazone on bone in post-menopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2013; 98: 4691-701.
46. Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-22.
47. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012; 55: 1953-62.
48. Levin D, Bell S, Sund R, et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 2015; 58: 493-504.
49. Lewis JD, Habel LA, Quesenberry CP, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 2015; 314: 265-77.
50. Colmers IN, Bowker SL, Johnson JA. Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 2012; 38: 475-84.
51. Chen S-W, Tsan Y-T, Chen J-D, et al. Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study. Diabetes Care 2013; 36: 369-75.
52. Lorenzo C, Haffner SM, Stancáková A, Laakso M. Relation of direct and surrogate measures of insulin resistance to cardiovascular risk factors in nondiabetic Finnish offspring of type 2 diabetic individuals. J Clin Endocrinol Metab 2010; 95: 5082-90.